

# NantHealth Expands Adoption of GPS Cancer™ with New Florida Genomics Lab License and Successful Adoption by Florida Community Oncologists

December 13, 2016

*Florida-based community oncologists leverage advanced molecular profile for decision support*

*Doctors report that patients find hope in additional care options with good outcomes*

CULVER CITY, Calif. & SARASOTA, Fla.--(BUSINESS WIRE)-- [NantHealth](#), Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has expanded adoption of [GPS Cancer](#), a comprehensive molecular profile, in Florida with the new Genomics Lab Licensing agreement with the state. The test is an advanced proteogenomics molecular analysis that helps oncologists guide a patient's treatment strategy, including informing choice of standard chemotherapy.

"By sequencing the entire genome, which consists of more than 20,000 genes and three billion base pairs and also performing protein expression with quantitative proteomics, the most actionable data about the biology of the tumor is available to the oncologist before treatment begins," said Dr. Patrick Soon-Shiong, founder and CEO of NantHealth. "The importance of having this information available is the ability for the treating physician to now know which drugs and chemotherapeutic agents have a higher probability of being effective or resistant based on the proteogenomic profile of the patient's tissue. Access to this level of data before a treatment decision is made was never available before and it is our hope that the GPS Cancer test will transcend our current 'trial and error' standards of care. By personalizing an informed decision through real world data, we can change cancer outcomes for the better."

One of the oncologists who has benefitted from the availability and use of GPS Cancer in Florida is Dr. [Steve Mamus](#), a Harvard trained molecular biologist, who has introduced the molecular profile to his practice at [the Cancer Center of Sarasota-Manatee](#) (CCSM), and has offered it to more than 100 patients since GPS Cancer's commercial availability in [June 2016](#). The Florida Genomics Lab Licensing agreement adds to the [global](#) community of healthcare providers, payers, and a Fortune 50 company that has committed to covering or using this comprehensive molecular profile. The GPS Cancer profile, which integrates quantitative proteomics with whole genome (DNA) and transcriptome (RNA) sequencing, is the only integrated comprehensive molecular test of its type conducted in CLIA-certified and CAP-accredited laboratories. It provides oncologists with a comprehensive molecular profile of a patient's cancer to inform personalized treatment strategies. GPS Cancer provides key insights based on the unique biology of a patient's tumor—from the DNA to the RNA to the protein. This rich information helps doctors build more effective treatment plans based on FDA-approved drugs and active clinical trials, while enabling cancer researchers to design new clinical trials that harness the potential of the immune system.

"What's so unique about GPS Cancer is that it can predict whether a particular cancer will respond to chemotherapy, targeted therapy or immunotherapy before a patient is treated," said Steve Mamus, MD, Cancer Center of Sarasota-Manatee. "As a physician, it's imperative that I'm able to do

everything I can to improve that outcome on [my patients'] behalf. Since GPS Cancer is the most advanced test of its kind currently on the market, it empowers us to better identify and offer treatments for our patients. This approach is revolutionary for oncologists and a major initiative in striving towards personalized care.”

To learn more about Dr. Mamus and specific use cases with his patients and others, please visit [here](#).

### **Cautionary Note Concerning Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.

### **About NantHealth, Inc.**

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit [www.nanthealth.com](http://www.nanthealth.com) and follow Dr. Soon-Shiong on Twitter [@DrPatSoonShiong](#).

### **About GPS Cancer™**

GPS Cancer™ is a comprehensive molecular profile available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with unprecedented insight into the molecular signature of each patient’s cancer to inform personalized treatment strategies. GPS Cancer profiling is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for the QUILT programs. GPS Cancer is the most unique and comprehensive test available on the market today; this is the first test that has transcended beyond the genome and crossed to the proteome. For more information, visit [www.gpscancer.com](http://www.gpscancer.com).



View source version on [businesswire.com](http://www.businesswire.com/news/home/20161213005297/en/): <http://www.businesswire.com/news/home/20161213005297/en/>

NantWorks

Jen Hodson, 562-397-3639

[johodson@nantworks.com](mailto:johodson@nantworks.com)

Source: NantHealth, Inc.